Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
BBT-176-ONC-001 trial: what clinicians have said so far
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
- NCT04820023 ↗
- Terminated
- Bridge Biotherapeutics, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on BBT-176-ONC-001 (BBT-176 in advanced NSCLC with progression after EGFR TKI treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BBT-176-ONC-001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BBT-176 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Agent
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- NSCLC
- Interventions
- BBT-176, QD; BBT-176, BID
- Arms
- 20mg QD · Experimental
- 80mg QD · Experimental
- 160mg QD · Experimental
- 320mg QD · Experimental
- 480mg QD · Experimental
- 600mg QD · Experimental
- 160mg, BID · Experimental
- 200mg, BID · Experimental
- 240mg, BID · Experimental
- Enrollment
- 45
- Primary outcomes
- (Part 1) Incidence of Adverse Events and Clinical Laboratory Abnormalities Defined as Dose-limiting Toxicities (DLTs)
- (Part 2) Objective Response Rate (ORR)
- Sponsor
- Bridge Biotherapeutics, Inc.
- Start
- Apr 2, 2021
- Primary completion
- Nov 29, 2023
- Results posted
- Yes
- Registry record
- NCT04820023 · updated Jun 6, 2025
Publications
linked from the registry- Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901. PubMed 37249619